Polymedco Announces: New Published Research Supports Fecal Immunochemical Testing (FIT) as the Most Clinically and Cost Effective Noninvasive Colorectal Cancer Screening (CRC) method

, /PRNewswire/ -- A recent study published in the JAMA Network Open demonstrates that annual FIT testing is more effective than both triannual blood-based tests and multi-target stool DNA (mt-sDNA) tests in terms of life years gained and cost efficiency as part of CRC programs.¹

Key findings from the study include:

1. Annual FIT-based screening produced fewer CRC cases, fewer CRC deaths and more life years gained versus all other strategies, even at real-world adherence rates.
2. Every screening strategy that was modeled reduced treatment costs and yielded quality adjusted life year (QALY) gains, but only FIT-based screening yielded net cost savings versus no screening due to its more substantial reduction in treatment costs.

The most widely utilized FIT test in the US is OC-Auto^®FIT, a noninvasive colorectal screening solution that detects non-visible blood in the stool.

"This independent research provides clinicians and health systems with unbiased data to guide critical decisions about colorectal cancer screening," said Chief Executive Officer, Doug White at Polymedco. "The evidence is clear: screening annually with a method like OC-Auto FIT improves outcomes and delivers greater cost-effectiveness than other noninvasive options."

The study compared FIT with other noninvasive screening methods, including mt-sDNA tests and blood-based tests. The researchers used the Colorectal Cancer Simulated Population Model for Incidence and Natural History (CRC-SPIN) to assess the cost-effectiveness and clinical outcomes associated with the currently available noninvasive CRC screening strategies in a simulated population with relatively low screening adherence.

Independent data consistently demonstrates that OC-Auto FIT provides the best balance of accuracy, accessibility, and affordability.

Link to the article Cost-Effectiveness of Noninvasive Colorectal Cancer Screening in Community Clinics | Gastroenterology and Hepatology | JAMA Network Open | JAMA Network

About OC-Auto FIT

OC-Auto FIT is the most widely utilized noninvasive, guideline-recommended FIT test, supported by published clinical outcome data. Designed for early detection, this test identifies blood in stool and has demonstrated a reduction in CRC incidence, increased adherence to screening, and lower CRC mortality rates. ^2,3 

About Polymedco

Polymedco partners with healthcare systems, payers, and providers to develop best-in-class screening programs for early disease detection.

Connect with Polymedco:
www.polymedco.com | LinkedIn: linkedin.com/company/polymedco | Facebook: facebook.com/Polymedco

Intended Use: OC-Auto Sensor io iFOB Test is designed to be used together as an immunoassay test system. The test system is intended for the qualitative detection of fecal occult blood in feces by professional laboratories. The automated test is used for the measurement of fecal occult blood and is useful as an aid to detect blood in stool when lower gastrointestinal bleeding may be suspected.

For more information: Polymedco Communications | Anthony Bercaw | [email protected]
*Perfect adherence assumes 100% screening and follow-up colonoscopy.
**Realistic adherence assumes 45% FIT or mt-sDNA screening, with 40% follow-up colonoscopy compliance.
¹ Nascimento de Lima P, Matrajt L, Coronado G, et al. Cost-Effectiveness of Noninvasive Colorectal Cancer Screening in Community Clinics. JAMA Netw Open. 2025;8(1):e2454938. doi:10.1001/jamanetworkopen.2024.54938
² Levin TR, Corley DA, Jensen CD, et al. Effects of Organized Colorectal Cancer Screening on Cancer Incidence and Mortality in a Large Community-Based Population. Gastroenterology. 2018;155(5):1383-1391.e5. doi:10.1053/j.gastro.2018.07.017
³ US Preventive Services Task Force, Davidson KW, Barry MJ, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(19):1965-1977. doi:10.1001/jama.2021.6238

81243-00

SOURCE Polymedco, LLC